Ovarian Cancer
Reports from the United States, United Kingdom and Japan describe recent advances in ovarian cancer research
Published in Clinical Trials Week, September 25th, 2006
Study 1: Patients with platinum and paclitaxel-resistant ovarian cancer responded to weekly paclitaxel (80 mg/m2) in a phase II trial.
According to a recent report published in the journal Gynecologic Oncology, researchers in the United States conducted a study "to evaluate the activity of single agent weekly paclitaxel in patients with both platinum and paclitaxel (delivered every 3 weeks) resistant ovarian cancer. Forty-eight patients with platinum and paclitaxel-resistant ovarian cancer (defined as progression during, or recurrence...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2006-09-25)
More Articles from Clinical Trials Week
- Alzheimer Disease
Accera initiates phase II trial for age associated memory impairment therapy - Clinical Trials
Atrial fibrillation incidence in chronic heart failure patients is reduced with candesartan - Clinical Trials
Starpharma initiates U.S. NIH-funded trial of microbicide for sexually transmitted diseases - Leukemia
Childhood T-lineage acute lymphoblastic leukemia associated with high expression of Delta TA-p73 - Urology
Oxybutynin appears well tolerated compared to tolterodine for overactive bladder - Alzheimer Disease
Memantine is safe and effective treatment for mild to moderate Alzheimer disease - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
